通过使用人性化的单克隆抗体,有效预防和治疗对小鼠和子的A型肉毒毒中毒的保护
Chi Ho Yu1, Young-Jo Song1, Dong Hyun Song1
1Agency for Defense Development, Yuseong, P.O. Box 35, Daejeon 305-600, Republic of Korea.
Toxins
|March 26, 2025
概括
一种新的人性化单克隆抗体 (HZ45 mAb) 有效地预防和治疗由强烈的肉毒神经毒素 (BoNTs) 引起的肉毒症. 这种抗体在小鼠中提供100%的保护,在子中提供治疗效益,证明了其作为新疗法的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肉毒神经毒素 (BoNTs) 是非常强大的毒素,会导致,被归类为A类毒素.
- 抗体疗法是毒素介导疾病的有效治疗方法.
- 肉毒仍然是一个严重的健康问题,需要采取有效的对策.
研究的目的:
- 开发和评估一种人性化的单克隆抗体 (HZ45 mAb),用于预防和治疗肉毒.
- 评估HZ45 mAb对肉毒神经毒素血清型A (BoNT/A) 的疗效.
主要方法:
- 使用混合体技术和菌体显示器生成HZ45 mAb.
- 在体内模型 (小鼠和子) 中评估BoNT/A的HZ45 mAb中和.
- 基于生存率和治疗时间表的保护和治疗疗效的评估.
主要成果:
- 在小鼠中,HZ45 mAb在0.1毫克/小鼠剂量下对BoNT/A的100LD50提供了100%的保护.
- 在子中,HZ45 mAb的5毫克剂量在暴露于BoNT/A.50的10 LD50后长达8小时时时给予治疗疗效.
- 在小鼠和子中,HZ45 mAb成功地预防了肉毒性中毒.
结论:
- 人性化单克隆抗体HZ45 mAb是预防和治疗甲型肉毒中毒的有希望的候选者.
- HZ45 mAb通过结合其重链受体域来中和BoNT/A,阻止细胞进入.
- 该研究验证了HZ45 mAb在临床前模型中的有效性,支持其作为药物干预的潜力.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
636
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
636
Anticholinesterase Agents: Poisoning and Treatment
763
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
763
Hybridoma Technology
13.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.9K
Myasthenia Gravis: Overview and Treatment
1.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.0K
Prevention of Further Absorption of Poison
777
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
777
Cross-reactivity
30.9K
Overview
30.9K


